Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch
  

Teva Pharmaceutical Industries Ltd patents

Recent patent applications related to Teva Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd is listed as an Agent/Assignee. Note: Teva Pharmaceutical Industries Ltd may have other listings under different names/spellings. We're not affiliated with Teva Pharmaceutical Industries Ltd, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "T" | Teva Pharmaceutical Industries Ltd-related inventors




Date Teva Pharmaceutical Industries Ltd patents (updated weekly) - BOOKMARK this page
10/12/17Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
09/21/17Treatment of glaucoma using laquinimod
09/21/17Treatment of crohn's disease with laquinimod
09/14/17Treatment of lupus nephritis using laquinimod
08/24/17Treatment of bdnf-related disorders using laquinimod
08/17/17Pharmaceutical compositions of memantine
08/17/17Treatment of ocular inflammatory diseases using laquinimod
08/10/17Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
08/10/17Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
07/27/17Use of laquinimod to delay huntington's disease progression
07/13/17Process for manufacturing glatiramer acetate product
06/08/17Devices and methods for preparing gastroretentive dosage forms
06/01/17Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
05/25/17Rituximab induction therapy followed by glatiramer acetate therapy
05/18/17Treatment of crohn's disease with laquinimod
05/11/17Treatment of multiple sclerosis with laquinimod
05/11/17Treatment of glaucoma using laquinimod
04/20/17Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
04/13/17Use of laquinimod to delay huntington's disease progression
03/16/17Transmucosal delivery of laquinimod by oral patches
03/09/17N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
02/02/17Treatment of glaucoma using laquinimod
02/02/17Combination formulation of laquinimod and glatiramer acetate with amino acids
01/26/17Treatment of crohn's disease with laquinimod
01/12/17Treatment of multiple sclerosis with combination of laquinimod and flupirtine
12/15/16Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
11/17/16Treatment of crohn's disease using low doses of laquinimod
11/03/16Use of rasagiline for the treatment of restless legs syndrome
11/03/16Treatment of multiple sclerosis with combination of laquinimod and teriflunomide
10/27/16Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders
10/27/16Select single nucleotide polymorphisms predictive of response to glatiramer acetate
10/13/16Formulations of 6-mercaptopurine
10/13/16Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy
10/13/16Laquinimod for reducing thalamic damage in multiple sclerosis
10/13/16Treatment of crohn's disease with laquinimod
09/29/16Treatment of multiple sclerosis with combination of laquinimod and fingolimod
09/29/165-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
09/22/16Laquinimod combination therapy for treatment of multiple sclerosis
08/25/16Treatment of bdnf-related disorders using laquinimod
08/18/16Treatment of multiple sclerosis with combination of laquinimod and fampridine
07/28/16Method of inducing anti-glatiramer acetate antibody response
07/28/16Treatment of lupus arthritis using laquinimod
07/28/16Process for manufacturing glatiramer acetate product
07/14/16Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
07/14/16Gene expression biomarkers of laquinimod responsiveness
07/14/16Novel estrogen receptor mutations and uses thereof
07/07/16Transmucosal delivery of glatiramer acetate
06/30/16Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy
06/16/16Treatment of multiple sclerosis with combination of laquinimod and flupirtine
06/16/16Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
06/09/16Crystals of laquinimod sodium and improved process for the manufacture thereof
06/02/16N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
06/02/16N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
03/24/16Treatment of multiple sclerosis with laquinimod
03/17/16Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
03/17/16Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
02/18/16Crystals of laquinimod sodium and improved process for the manufacture thereof
02/11/16Transdermal formulations of laquinimod
02/11/16Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
01/28/16Rituximab induction therapy followed by glatiramer acetate therapy
01/28/16Process for the measurement of the potency of glatiramer acetate
01/21/16Formulations of an albumin hgh fusion protein
01/07/16Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
01/07/16Use of high dose laquinimod for treating multiple sclerosis
12/31/15Analogs of pridopidine, their preparation and use
Patent Packs
12/17/15Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
12/03/15Expandable gastroretentive dosage form
11/19/15Oral transmucosal delivery of glatiramer acetate
10/29/15Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
10/15/15Formulations of 6-mercaptopurine
10/01/15Determination of single nucleotide polymorphisms useful to predict response for rasagiline
09/24/15Use of high dose laquinimod for treating multiple sclerosis
08/27/15Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
07/30/15Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
07/23/15Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia
06/25/15Use of laquinimod to delay huntington's disease progression
06/18/15Treatment of multiple sclerosis with laquinimod
05/21/15Treatment of glaucoma using laquinimod
04/30/15Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
04/23/15Genetic markers predictive of response to glatiramer acetate
Patent Packs
04/09/15Nilotinib salts and crystalline forms thereof
04/02/15Laquinimod combination therapy for treatment of multiple sclerosis
04/02/15Process for the measurement of the potency of glatiramer acetate
03/26/15Treatment of lupus arthritis using laquinimod
03/19/15Use of rasagiline for the treatment of restless legs syndrome
02/26/15Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
02/12/15Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
02/12/153-keto-n-propargyl-1-aminoindan
02/05/15Treatment of multiple sclerosis with combination of laquinimod and fingolimod
02/05/15Treatment of multiple sclerosis with combination of laquinimod and flupirtine
02/05/15Treatment of lupus nephritis using laquinimod
02/05/15Crystalline solid rasagiline base
01/29/15Rasagiline orally disintegrating compositions
12/18/14Treatment of inflammatory bowel disease with 6-mercaptopurine
12/11/14Deuterium enriched rasagiline
11/20/14Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
10/30/14Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
10/02/14Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
09/18/14Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia in pediatric patients
09/18/14Processes for coating a carrier with microparticles
09/18/14Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
09/18/14Rituximab induction therapy followed by glatiramer acetate therapy
09/18/14Crystals of laquinimod sodium and improved process for the manufacture thereof
09/18/14Custirsen treatment with reduced toxicity
09/18/14Anti-clusterin monotherapy for cancer treatment
09/11/14Raltegravir salts and crystalline forms thereof
08/28/14Rasagiline for parkinson's disease modification
08/21/14Treatment of progressive forms of multiple sclerosis with laquinimod
07/17/14Formulations of albu-bche, preparation and uses thereof
07/17/14Lyophilization process
Social Network Patent Pack
07/17/14Treatment of crohn's disease with laquinimod
07/10/14Dispersions of rasagiline citrate
07/10/14Characterizing a glatiramer acetate related drug product
07/03/14Delayed release rasagiline formulation
06/19/14Crystals of laquinimod sodium, and process for the manufacture thereof
06/12/14Formulations of 6-mercaptopurine
06/12/14Fusion of human growth hormone and albumin formulation and uses thereof
05/08/14Amine salts of laquinimod
04/17/14Treatment of multiple sclerosis with laquinimod
04/17/14Laquinimod for reducing thalamic damage in multiple sclerosis
Patent Packs
04/17/14Biomarkers predictive for clinical response for glatiramer acetate
04/03/14New intermediates and processes for preparing ticagrelor
03/27/14Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
03/27/14Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
03/06/14Bche albumin fusions for the treatment of cocaine abuse
02/27/14Treatment of crohn's disease with laquinimod
02/20/14Pharmaceutical compositions of memantine
02/20/14Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
02/20/14Parenteral formulations of rasagiline
02/13/14Laquinimod for treatment of gaba mediated disorders
02/13/14Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders
01/30/14Dose counter and recording method
01/23/14Stable laquinimod preparations
01/16/14Treatment of multiple sclerosis with combination of laquinimod and fampridine
01/16/14Laquinimod formulations without alkalizing agent
12/26/13Dry formulations of aripiprazole
12/26/13N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
12/05/13Treatment of ocular inflammatory diseases using laquinimod
11/21/13Method for treating non-small cell lung cancer
11/14/13Inhalers and housing caps for inhalers
11/14/13Use of high dose laquinimod for treating multiple sclerosis
10/17/13Treatment of multiple sclerosis with laquinimod
10/03/13Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
08/22/13N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
08/08/13Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
07/18/13Treatment of lupus arthritis using laquinimod
07/04/13Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use
06/27/13Low frequency glatiramer acetate therapy
06/20/13Nilotinib salts and crystalline forms thereof
05/23/13Stable formulations of recombinant human albumin-human granulocyte colony stimulating factor
Patent Packs
05/16/13Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
04/18/13Nilotinib hcl crystalline forms
04/18/13Treatment of multiple sclerosis with combination of laquinimod and fingolimod
04/11/13R(+)-n-methyl-propargyl-aminoindan
04/11/13Rasagiline citramide
04/11/13R(+)-n-formyl-propargyl-aminoindan
01/24/13Parenteral formulations of peptides for the treatment of systematic lupus erythematosus
12/13/12Solid state forms of sitagliptin salts
12/06/12Process for the measurement of the potency of glatiramer acetate
11/29/12Stable laquinimod preparations
10/18/12Delayed release rasagiline formulation
09/06/12Stable laquinimod preparations
08/30/12Solid forms of aliskiren hemifumarate and processes for preparation thereof
07/12/12Stable combinations of amlodipine besylate and benazepril hydrochloride
04/26/12Delayed release rasagiline malate formulation
04/19/12Solid states of aliskiren free base
03/22/12Low frequency glatiramer acetate therapy
02/23/12Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
02/23/12Stable pharmacologically active compositions including vitamin d containing and corticosteroid compounds with low ph compatibility
02/23/12Solid states of atorvastatin potassium
Social Network Patent Pack
02/02/12Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
02/02/12Polymorphic forms of aliskiren hemifumarate and process for preparation thereof
11/17/11Process for preparing and drying solid rasagiline base
11/10/11Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
10/13/11Stable laquinimod preparations
10/06/11Solid state forms of sitagliptin salts
08/04/11Process for the measurement of the potency of glatiramer acetate
05/19/11Sunitinib and salts thereof and their polymorphs
05/19/11Crystals of laquinimod sodium, and process for the manufacture thereof
05/12/11Crystals of laquinimod sodium, and process for the manufacture thereof
04/14/11Delayed release compositions
03/17/11Reduced volume formulation of glatiramer acetate and methods of administration
02/24/11Low frequency glatiramer acetate therapy
02/03/11Treatment of crohn's disease with laquinimod
12/23/10Solid states forms of varenicline salts and processes for preparation thereof
12/23/10Treatment of multiple sclerosis with laquinimod
12/16/10Crystalline form of febuxostat
12/02/10Method of delaying the onset of clinically definite multiple sclerosis
11/25/10Stable formulations of recombinant human albumin-human granulocyte colony stimulating factor
11/11/10Markers associated with the therapeutic efficacy of glatiramer acetate
Social Network Patent Pack
10/07/10Polymorphs of sunitinib base and processes for preparation thereof
09/30/10Solid state forms of sitagliptin salts
08/26/10Desloratadine crystalline forms mixtures having a low level of residual solvents
08/05/10Diastereomeric purification of rosuvastatin
07/29/10Processes for coating a carrier with microparticles
07/29/10Delayed release rasagiline citrate formulation
07/29/10Delayed release rasagiline base formulation
07/29/10Delayed release rasagiline formulation
07/29/10Delayed release rasagiline malate formulation
07/29/10Nilotinib hcl crystalline forms
07/22/10Preparation of retapamulin via its pleuromutilin-thiol precursor
07/01/10Solid composites of a calcium receptor-active compound
07/01/10Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
06/24/10Stable combinations of amlodipine besylate and benazepril hydrochloride
06/24/10Processes for preparing sunitinib and salts thereof
06/24/10Process for preparing intermediates of hmg-coa reductase inhibitors
06/24/10Processes for the preparation and purification of gabapentin enacarbil
06/24/10Preparation of gabapentin enacarbil intermediate
06/17/10Process for the synthesis of ramelteon and its intermediates
06/10/10Crystalline solid rasagiline base
06/10/10Crystalline solid rasagiline base
05/13/10Stable pharmaceutical formulations of montelukast sodium
05/06/10Crystalline forms of dexlansoprazole
04/22/10Tadalafil solid composites
04/01/102-n-{5-[ [4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
02/04/10Methods for preparing eszopiclone crystalline form a, substantially pure eszopiclone and optically enriched eszopiclone
01/21/10Nilotinib intermediates and preparation thereof
01/07/10Gabapentin enacarbil salts and processes for their preparation
12/24/09Processes for preparing prodrugs of gabapentin and intermediates thereof
12/17/09Atorvastatin formulation
Social Network Patent Pack
11/26/09Novel crystalline forms of armodafinil and preparation thereof
10/01/09Processes for preparing sunitinib and salts thereof
09/24/09Rosuvastatin calcium with a low salt content
08/20/09Process for preparing intermediates of hmg-coa reductase inhibitors
07/02/09Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
06/25/09Crystalline solids of carvedilol and processes for their preparation
06/04/09Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
05/07/09Amorphous and crystalline forms of ibandronate disodium
04/16/09Crystalline forms of ibandronic acid and processes for the preparation thereof
03/19/09Polymorphs of eszopiclone malate
03/19/09Rosuvastatin intermediates and process for the preparation of rosuvastatin
02/26/09Process for the measurement of the potency of glatiramer acetate







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Teva Pharmaceutical Industries Ltd in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Teva Pharmaceutical Industries Ltd with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';